(AGIO) Agios Pharm - Ratings and Ratios
Pyruvate Kinase Activator, IDH Inhibitor, Sickle Cell Therapy
AGIO EPS (Earnings per Share)
AGIO Revenue
Description: AGIO Agios Pharm
Agios Pharmaceuticals (NASDAQ:AGIO) is a biotechnology company listed on the NASDAQ stock exchange, operating within the biotechnology sub-industry. The companys stock performance is characterized by a current price of $37.06, indicating a potential undervaluation given its historical volatility and moving averages.
To assess the investment potential of AGIO, key financial metrics and ratios are crucial. The market capitalization stands at $2.1 billion, suggesting a mid-cap status that balances growth potential with relative stability. The Price-to-Earnings (P/E) ratio is 3.04, and the forward P/E is 2.47, indicating that the stock might be undervalued relative to its earnings. The Return on Equity (RoE) of 43.31% is significantly high, suggesting efficient use of shareholder equity.
From a trading perspective, AGIOs Average True Range (ATR) is $1.76, translating to a volatility of 4.75%. The stocks beta is 0.798, indicating lower volatility compared to the overall market. The 52-week high and low are $61.64 and $24.53, respectively, showing a considerable price range and potential for significant price movements.
To further evaluate AGIOs potential, its essential to consider key economic drivers and KPIs in the biotechnology sector, such as pipeline progress, regulatory approvals, and revenue growth from existing products. The companys ability to innovate and bring new therapies to market, as well as its financial health in terms of cash reserves and burn rate, are critical factors. Investors should monitor upcoming clinical trial results, FDA decisions, and partnerships or collaborations that could impact the stocks performance.
Given the current valuation and financial health indicators, AGIO presents an interesting case for investors. A thorough analysis of its product pipeline, upcoming milestones, and the competitive landscape in the biotechnology sector is necessary to make an informed investment decision. Key drivers such as revenue growth, successful trial outcomes, and strategic partnerships will be crucial in determining the stocks future performance.
AGIO Stock Overview
| Market Cap in USD | 2,073m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-07-24 |
AGIO Stock Ratings
| Growth Rating | -14.0% |
| Fundamental | 39.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -31.5% |
| Analyst Rating | 4.0 of 5 |
AGIO Dividends
Currently no dividends paidAGIO Growth Ratios
| Growth Correlation 3m | 32.6% |
| Growth Correlation 12m | -41.1% |
| Growth Correlation 5y | -20.7% |
| CAGR 5y | 6.11% |
| CAGR/Max DD 3y | 0.10 |
| CAGR/Mean DD 3y | 0.31 |
| Sharpe Ratio 12m | 1.04 |
| Alpha | -33.90 |
| Beta | 0.721 |
| Volatility | 48.56% |
| Current Volume | 603.4k |
| Average Volume 20d | 647.3k |
| Stop Loss | 34.7 (-5.7%) |
| Signal | 0.62 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (650.1m TTM) > 0 and > 6% of Revenue (6% = 2.45m TTM) |
| FCFTA -0.27 (>2.0%) and ΔFCFTA 11.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2322 % (prev 1819 %; Δ 502.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.28 (>3.0%) and CFO -406.0m <= Net Income 650.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 14.48 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (57.9m) change vs 12m ago 1.99% (target <= -2.0% for YES) |
| Gross Margin 85.10% (prev 75.45%; Δ 9.65pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 3.64% (prev 4.05%; Δ -0.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -2.84
| (A) 0.65 = (Total Current Assets 1.02b - Total Current Liabilities 70.4m) / Total Assets 1.47b |
| (B) -0.24 = Retained Earnings (Balance) -350.2m / Total Assets 1.47b |
| (C) -0.40 = EBIT TTM -447.8m / Avg Total Assets 1.12b |
| (D) -3.44 = Book Value of Equity -349.5m / Total Liabilities 101.7m |
| Total Rating: -2.84 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.99
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -33.10% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda -0.11 = -2.50 |
| 6. ROIC - WACC -38.73% = -12.50 |
| 7. RoE 43.31% = 2.50 |
| 8. Rev. Trend 93.64% = 4.68 |
| 9. Rev. CAGR 58.40% = 2.50 |
| 10. EPS Trend -7.61% = -0.19 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of AGIO shares?
Over the past week, the price has changed by +1.02%, over one month by +0.27%, over three months by +2.88% and over the past year by -19.00%.
Is Agios Pharm a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AGIO is around 32.03 USD . This means that AGIO is currently overvalued and has a potential downside of -12.91%.
Is AGIO a buy, sell or hold?
- Strong Buy: 3
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AGIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47.5 | 29.1% |
| Analysts Target Price | 47.5 | 29.1% |
| ValueRay Target Price | 35.8 | -2.6% |
Last update: 2025-09-12 04:30
AGIO Fundamental Data Overview
CCE Cash And Equivalents = 938.9m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 3.1603
P/E Forward = 2.4655
P/S = 50.7171
P/B = 1.5137
Beta = 0.867
Revenue TTM = 40.9m USD
EBIT TTM = -447.8m USD
EBITDA TTM = -442.6m USD
Long Term Debt = 31.3m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 17.6m USD (from shortTermDebt, last quarter)
Debt = 48.9m USD (Calculated: Short Term 17.6m + Long Term 31.3m)
Net Debt = -32.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.18b USD (2.07b + Debt 48.9m - CCE 938.9m)
Interest Coverage Ratio = unknown (Ebit TTM -447.8m / Interest Expense TTM 0.0)
FCF Yield = -33.10% (FCF TTM -391.5m / Enterprise Value 1.18b)
FCF Margin = -957.9% (FCF TTM -391.5m / Revenue TTM 40.9m)
Net Margin = 1590 % (Net Income TTM 650.1m / Revenue TTM 40.9m)
Gross Margin = 85.10% ((Revenue TTM 40.9m - Cost of Revenue TTM 6.09m) / Revenue TTM)
Tobins Q-Ratio = -3.38 (set to none) (Enterprise Value 1.18b / Book Value Of Equity -349.5m)
Interest Expense / Debt = 19.64% (Interest Expense 9.60m / Debt 48.9m)
Taxrate = 6.16% (44.2m / 718.0m)
NOPAT = -447.8m (EBIT -447.8m, no tax applied on loss)
Current Ratio = 14.48 (Total Current Assets 1.02b / Total Current Liabilities 70.4m)
Debt / Equity = 0.04 (Debt 48.9m / last Quarter total Stockholder Equity 1.37b)
Debt / EBITDA = -0.11 (Net Debt -32.1m / EBITDA -442.6m)
Debt / FCF = -0.12 (Debt 48.9m / FCF TTM -391.5m)
Total Stockholder Equity = 1.50b (last 4 quarters mean)
RoA = 44.19% (Net Income 650.1m, Total Assets 1.47b )
RoE = 43.31% (Net Income TTM 650.1m / Total Stockholder Equity 1.50b)
RoCE = -29.23% (Ebit -447.8m / (Equity 1.50b + L.T.Debt 31.3m))
RoIC = -29.84% (NOPAT -447.8m / Invested Capital 1.50b)
WACC = 8.89% (E(2.07b)/V(2.12b) * Re(8.67%)) + (D(48.9m)/V(2.12b) * Rd(19.64%) * (1-Tc(0.06)))
Shares Correlation 3-Years: 87.88 | Cagr: 0.50%
Discount Rate = 8.67% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -391.5m)
Revenue Correlation: 93.64 | Revenue CAGR: 58.40%
Rev Growth-of-Growth: -21.51
EPS Correlation: -7.61 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 60.52
Additional Sources for AGIO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle